Indomethacin-based stimuli-responsive micelles combined with paclitaxel to overcome multidrug resistance

Shuanghu Wang, Xueying Tan, Shujuan Li, Yunfang Zhou, Peiwu Geng, Ailian Hua, Aiping Deng, Zhihong Yu

Oncotarget · 2017 · 16 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

// Shuanghu Wang 1, * , Xueying Tan 2, * , Shujuan Li 2 , Yunfang Zhou 1 , Peiwu Geng 1 , Ailian Hua 1 , Aiping Deng 3 and Zhihong Yu 3 1 The Laboratory of Clinical Pharmacy, The Sixth Affiliated Hospital of Wenzhou Medical University, The People's Hospital of Lishui, Lishui 323000, China 2 College of Pharmacy, Zhejiang Pharmaceutical College, Ningbo 315000, China 3 Department of Pharmacy, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430000, China * These authors have contributed equally to this work Correspondence to: Zhihong Yu, email: zhihong_yu@yeah.net Keywords: breast cancer; multidrug resistance; paclitaxel; indomethacin; drug delivery system Received: June 06, 2017      Accepted: November 19, 2017      Published: November 30, 2017 ABSTRACT Development of multidrug resistance against antitumor agents is a major limiting factor for the successful chemotherapy. Currently, both amphiphilic polymeric micelles and chemosensitizers have been proposed to overcome MDR during chemotherapy. Herein, the redox-responsive polymeric micelles composed of dextran and indomethacin (as chemosensitizer) using a disulfide bond as the linker are prepared (DEX-SS-IND) for delivery of antitumor agent paclitaxel (PTX). The high level of glutathione in tumor cells selectively breaks the disulfide bond, leading to the rapid breakdown and deformation of redox-responsive polymeric micelles. The data show that DEX-SS-IND can spontaneously form the stable micelles with high loading content (9.48 ± 0.41%), a favorable size of 45 nm with a narrow polydispersity (0.157), good stability, and glutathione-triggered drug release behavior due to the rapid breakdown of disulfide bond between DEX and IND. In vitro antitumor assay shows DEX-SS-IND/PTX micelles effectively inhibit the proliferation of PTX-resistant breast cancer (MCF-7/PTX) cells. More impressively, DEX-SS-IND/PTX micelles possess the improved plasma pharmacokinetics, enhanced antitumor efficacy on tumor growth in the xenograft models of MCF-7/PTX cells, and better in vivo safety. Overall, DEX-SS-IND/PTX micelles display a great potential for cancer treatment, especially for multidrug resistance tumors.

References

21